AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
AstraZeneca (AZN) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its PD-L1 inhibitor Imfinzi (durvalumab) as a treatment for certain patients with primary advanced or recurrent endometrial cancer.The CHMP recommended the approval of Imfinzi plus chemotherapy, followed by Imfinzi and Lynparza as a first-line treatment for patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer.The CHMP ...